Cocaine Directly Inhibits α6-Containing Nicotinic Acetylcholine Receptors in Human SH-EP1 Cells and Mouse VTA DA Neurons.
SH-EP1 cells
VTA, dopamine neurons, patch clamp
cocaine
nicotinic acetylcholine receptor
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
10
2018
accepted:
21
01
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
7
3
2019
Statut:
epublish
Résumé
Alpha6-containing nicotinic acetylcholine receptors are primarily found in neurons of the midbrain dopaminergic (DA) system, suggesting these receptors are potentially involved in drug reward and dependence. Here, we report a novel effect that cocaine directly inhibits α6N/α3Cβ2β3-nAChR (α6*-nAChRs) function. Human α6*-nAChRs were heterologously expressed within cells of the SH-EP1 cell line for functional characterization. Mechanically dissociated DA neurons from mouse ventral tegmental area (VTA) were used as a model of presynaptic α6*-nAChR activation since this method preserves terminal boutons. Patch-clamp recordings in whole-cell configuration were used to measure α6*-nAChR function as well as evaluate the effects of cocaine. In SH-EP1 cells containing heterologously expressed human α6*-nAChRs, cocaine inhibits nicotine-induced inward currents in a concentration-dependent manner with an IC
Identifiants
pubmed: 30837868
doi: 10.3389/fphar.2019.00072
pmc: PMC6383119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
72Subventions
Organisme : NIDA NIH HHS
ID : R01 DA011064
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA042749
Pays : United States
Références
J Pharmacol Exp Ther. 1999 Jun;289(3):1229-36
pubmed: 10336510
Mol Pharmacol. 2000 Jul;58(1):109-19
pubmed: 10860932
Neuropharmacology. 2000 Oct;39(13):2570-90
pubmed: 11044728
J Neurosci. 2001 Mar 1;21(5):1452-63
pubmed: 11222635
Neuropsychopharmacology. 2001 May;24(5):576-89
pubmed: 11282258
J Comp Neurol. 2002 Mar 12;444(3):260-74
pubmed: 11840479
J Neurosci. 2002 Apr 15;22(8):3269-76
pubmed: 11943828
J Pharmacol Exp Ther. 2002 Jun;301(3):1119-25
pubmed: 12023545
World J Biol Psychiatry. 2002 Jul;3(3):150-5
pubmed: 12478880
Trends Pharmacol Sci. 2003 Jan;24(1):44-7
pubmed: 12498731
Neuron. 2003 Feb 20;37(4):577-82
pubmed: 12597856
Behav Neurosci. 2003 Aug;117(4):860-5
pubmed: 12931970
J Biol Chem. 2004 Sep 3;279(36):37842-51
pubmed: 15234980
Eur Neuropsychopharmacol. 2005 Mar;15(2):219-25
pubmed: 15695068
J Neurosci. 2005 Apr 6;25(14):3674-9
pubmed: 15814798
Behav Brain Res. 2006 Mar 15;168(1):120-6
pubmed: 16313978
J Natl Med Assoc. 2005 Nov;97(11):1504-15
pubmed: 16334497
J Physiol. 2006 Oct 1;576(Pt 1):103-18
pubmed: 16825297
Psychopharmacology (Berl). 2007 Feb;190(2):189-99
pubmed: 17061109
J Mol Biol. 2007 Jun 15;369(4):895-901
pubmed: 17481657
Neuropsychopharmacology. 2008 Jul;33(8):1779-97
pubmed: 17928814
Neuron. 2008 Oct 9;60(1):123-36
pubmed: 18940593
J Physiol. 2009 Jan 15;587(2):345-61
pubmed: 19047205
Acta Pharmacol Sin. 2009 Jun;30(6):740-51
pubmed: 19498417
Acta Pharmacol Sin. 2009 Jun;30(6):805-17
pubmed: 19498421
Acta Pharmacol Sin. 2009 Jun;30(6):851-8
pubmed: 19498424
Brain Res Bull. 2010 Jan 15;81(1):120-4
pubmed: 19665529
Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79
pubmed: 19959340
J Neurosci. 2010 Oct 13;30(41):13814-25
pubmed: 20943922
J Neurosci. 2011 Feb 16;31(7):2537-48
pubmed: 21325521
Exp Clin Psychopharmacol. 2011 Jun;19(3):203-14
pubmed: 21480727
Biochem Pharmacol. 2011 Oct 15;82(8):800-7
pubmed: 21787755
J Pharmacol Exp Ther. 2011 Nov;339(2):678-86
pubmed: 21856860
Sci Transl Med. 2011 Nov 2;3(107):107ra109
pubmed: 22049069
J Mol Model. 2012 Jun;18(6):2279-89
pubmed: 22116611
J Med Chem. 2012 Nov 26;55(22):9929-45
pubmed: 23025891
Mol Pharmacol. 2013 Sep;84(3):393-406
pubmed: 23788655
J Clin Oncol. 2013 Nov 20;31(33):4188-98
pubmed: 24145348
Clin Hemorheol Microcirc. 2014;57(4):385-94
pubmed: 24177220
Neuropsychopharmacology. 2014 Apr;39(5):1222-31
pubmed: 24304823
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):966-71
pubmed: 24367074
BMC Res Notes. 2014 Mar 25;7:173
pubmed: 24666782
Nat Commun. 2014 May 21;5:3925
pubmed: 24968237
Neuropsychopharmacology. 2015 Jan;40(2):350-60
pubmed: 25035086
Drug Alcohol Depend. 2014 Sep 1;142:1-13
pubmed: 25066468
PLoS One. 2014 Jul 28;9(7):e103244
pubmed: 25068303
Front Synaptic Neurosci. 2014 Sep 04;6:19
pubmed: 25237305
Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1637-61
pubmed: 25311945
Acta Pharmacol Sin. 2016 Aug;37(8):1020-30
pubmed: 27374488
Brain Res. 2017 Jan 1;1654(Pt B):165-170
pubmed: 27485657
J Neurosci. 2016 Oct 19;36(42):10759-10768
pubmed: 27798131
Science. 1987 Sep 4;237(4819):1219-23
pubmed: 2820058
Addict Biol. 2017 Sep 13;:
pubmed: 28901722
Acta Pharmacol Sin. 2018 Oct;39(10):1571-1581
pubmed: 29795357
Eur J Pharmacol. 2019 Feb 15;845:1-7
pubmed: 30529197
J Neurosci. 1988 Jan;8(1):100-12
pubmed: 3339402
J Pharmacol Exp Ther. 1995 Jul;274(1):396-403
pubmed: 7616424
J Neurosci. 1998 Jan 1;18(1):488-98
pubmed: 9412525